Reuters logo
5 months ago
BRIEF-Sunovion submits supplemental new drug application to FDA for Aptiom
March 13, 2017 / 1:38 PM / 5 months ago

BRIEF-Sunovion submits supplemental new drug application to FDA for Aptiom

March 13 (Reuters) - Sumitomo Dainippon Pharma Co Ltd :

* Sunovion submits supplemental new drug application to FDA for use of Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures in children 4 years of age and older

* Sunovion - in SNDA submission, Sunovion will also include data from three clinical trials conducted by partner Bial-Portela

* Sunovion - planning a phase 3 clinical study in children younger than four years of age Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below